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Background: Myxomatous mitral valve disease (MVD) is the most common acquired heart disease in dogs, and the
Cavalier King Charles Spaniel (CKCS) is the most studied breed because of the high prevalence, early onset and
hereditary component evidenced in the breed. MVD has different severity levels, and there are many practical
limitations in identifying its asymptomatic stages. Proteomic techniques are valuable for studying the proteins and
peptides involved in cardiovascular diseases, including the period prior to the clinical onset of the disease. The aim
of this study was to identify the serum proteins that were differentially expressed in healthy CKCS and those
affected by MVD in mild to severe stages. Proteomics analysis was performed using two-dimensional gel
electrophoresis separation and a bioinformatics analysis for the detection of differentially expressed spots. In a
comparative analysis, protein spots with a p < 0.05 (ANOVA) were considered statistically significant and were
excised from the gels for analysis by MALDI–TOF–MS for protein identification.
Results: Eight proteins resulted differentially expressed among the groups and significantly related to the
progression of the disease.
In mild affected group versus healthy dogs complement factor H isoform 2, inhibitor of carbonic anhydrase,
hemopexin, dystrobrevin beta isoform X7 and CD5 molecule-like resulted to be down-regulated, whereas
fibronectin type-III domain-containing protein 3A isoform X4 was up-regulated.
In severe affected dogs versus healthy group complement factor H isoform 2, calpain-3 isoform X2, dystrobrevin
beta isoform X7, CD5 molecule-like and l-2-hydroxyglutarate dehydrogenase resulted to be down-regulated.
Complement factor H isoform 2, calpain-3 isoform X2, dystrobrevin beta isoform X7, CD5 molecule-like and
hydroxyglutarate dehydrogenase were found to be down-regulated in mild affected group versus healthy dogs. All
of these proteins except complement factor H followed a decreasing trend according to the progression of the
pathology.
Conclusion: The differential expression of serum proteins demonstrates the possibility these might be valuable for
the detection and monitoring of the disease. Further longitudinal studies are required to determine whether
differential protein expression occurs sufficiently early in the progression of the disease and with sufficient
predictive value to allow proteomics analysis to be used as an early detection and on-line diagnostic tool.
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Myxomatous mitral valve disease (MVD) is the most
prevalent acquired heart disease in dogs, and is the most
common cause of left heart failure, particularly in older
and small breed dogs [1].
The Cavalier King Charles Spaniel (CKCS) is an excep-
tion, and the interesting in study MVD in this breed
comes from the evidence that CKCS shows the youngest
onset and the highest incidence, compared with other
breeds [1–5].
The cause of canine MVD is currently unknown,
although a genetic predisposition has been proven [2, 4, 6].
MVD has also been increasingly considered as the re-
sult of certain effector proteins released in response to
mechanical or chemical stimuli through signalling path-
ways rather than only an age-related disease [6]. The sig-
nalling mechanisms at the core of MVD have been
investigated by the use of new technologies, and ad-
vances in proteomic techniques have improved the tools
available for studying cardiovascular diseases [7]. The
proteome reflects all proteins and peptides that may be
related to certain genes and allows a more detailed
evaluation of disease status [8, 9]. In 2009, Lacerda et al.
conducted the first proteomic study on canine mitral
valve leaflet tissue obtained postmortem from healthy
dogs and from dogs with early and end-stage MVD.
More than 300 proteins were identified, and 117 of
these that were over- or under-expressed, which could
provide mechanistic clues into the pathogenesis of
MVD [3, 10].
In 2013, Gao et al. investigated plasma protein expres-
sion in human patients affected by degenerative or
rheumatic valvular disease and compared it with healthy
subjects [8]. They reported that few proteomic studies
on MVD have been done, and most of them studied tis-
sue, whereas the serum or plasma are ideal sources for
proteome analysis, as they are easily sampled and are
able to analyse processes in specific anatomical compart-
ments because blood flows in all tissues and is therefore
able to take up proteins secreted or shed by tissues [8].
Authors used a similar experimental approach with the
difference that they used the depletion of high abundant
proteins and described that Carbonic anhydrase protein
was over-represented.
In 2013, Tan et al. applied proteomic methods to
plasma samples collected from humans with mitral
regurgitation (MR) and with or without mitral valve
prolapse (MVP) [11]. This study revealed four pro-
teins differentially expressed with a presumptive role
in the pathogenesis of MVP: haptoglobin, platelet
basic protein and complement component C4b were
down-regulated and fibronectin was up-regulated in
MR patients with MVP versus the control cases (MR)
[11]. In 2014, Xuan et al. applied his experience inplasma proteomic studies to identify plasma protein
changes in congenital heart disease with regard to po-
tential clinical significance [8, 9, 11].
At present, in veterinary medicine there is no treat-
ment for the disease itself that can be applied on a large
population of patients (i.e. valve replacement and repair
surgery), and so the prevention of its occurrence is the
only strategy to reduce the incidence in dogs.
To date in order to reduce the prevalence of MVD in
CKCS, a breeding program has been conducted in
Sweden since 2001. This program was based on heart
auscultation, on pedigree analysis and on the indication
that dogs under the age of four years should not be bred
[12]. The effects of the breeding program were evaluated
by comparing the prevalence of heart murmur in CKCS
at 6 years of age in 2007 and 2009. No decrease in
the prevalence of the murmur was detected, indicat-
ing that the breeding program did not achieve the de-
sired effects [12, 13].
In 2016 the results of a mandatory breeding scheme
based on cardiac auscultation and on echocardiographic
detection of mitral valve prolapse, performed in
Denmark from 2002 to 2011 were published. The study
evidenced a significant reduction in risk of having a mi-
tral regurgitation murmur caused by MVD after a 8 to
10 year period [13]. Nevertheless same authors reported
of limitations to a wide application of the program, and
that may affect the use of this method in breeding
schemes including multicentre clinical examinations
(differences in echocardiographic equipment, technical
settings, replacing of the operators, and the changing in
the overall observer performance) [13].
To our knowledge there has been extensive research
into attempting to diagnose MVD, and more particu-
larly, to diagnose the onset of heart failure in dogs, but
none in which proteomic techniques on CKCD clinical
patients have been used. To date, there are no reports of
serum proteomic changes in dogs affected by MVD. The
aim of this study was to evaluate the serum protein pro-
file of healthy and MVD affected CKCS in order to
evaluate the physiological changes and the modifications
caused by MVD. These findings could provide new in-
sights into our understanding of the underlying mecha-
nisms and the changes from mild to severe stages. The
differential expression of the serum proteins moreover
could be helpful together with the current techniques in
the evaluation of the stage of the pathology, of the drug
administration outcome and of the disease progression.
Methods
The study was conducted on privately owned CKCS
prospectively recruited at the Cardiology Unit of the
Department of Veterinary Medicine, University of Milan
(DiMeVet).
Locatelli et al. BMC Veterinary Research  (2017) 13:43 Page 3 of 9A convenience sample of 12 CKCS was enrolled, 4
healthy dogs (control group) and 8 dogs affected by
MVD.
All of the owners signed an informed consent before
enrolling their dogs in the study. Each dog underwent a
complete physical examination aimed at evaluating the
general physical condition. The cardiovascular system
was evaluated by checking for the presence/absence of a
murmur, type and intensity of the murmur (grade I-VI/
VI), if present, and the point of maximum intensity.
Blood pressure was indirectly measured with a Doppler
method according to the ACVIM consensus statement
[14]. Once reliable consecutive readings were obtained,
the mean of five consecutive blood pressure measure-
ments was calculated [12, 15]. Blood was collected from
the jugular vein into 5-mL serum tubes and 2.5-mL
EDTA tubes after a 12-h fasting. A complete blood
count (CBC) was performed for each dog, and serum
samples were centrifuged within 30 min after collection
at 3000 × g for 5 min, followed by aliquoting of the
plasma. The total protein content and the blood glucose
of each sample were immediately evaluated. Serum pro-
tein amount was determined using the Bradford dye-
binding method (Protein Assay kit 2, Bio-Rad catalogue
n° 5000002) according to the manufacturer’s instruc-
tions. Subsequently, serum biochemistry, including cre-
atinine, urea and serum calcium, potassium, sodium and
chloride levels, was analysed. The remaining serum was
harvested and transferred into 1.5-mL plastic cryotubes,
and the samples were stored at -80°C for subsequent
analysis.
Thoracic radiographs in right lateral and dorsoventral
recumbency were obtained for all of the dogs included.
Each radiograph was evaluated for the presence/absence
of cardiomegaly, left atrial/ventricle enlargement, venous
congestion, and pulmonary edema.
Echocardiographic examination (2-D, M-mode, spec-
tral, and colour-flow Doppler) was performed by two
well-trained investigators using a machine equipped with
a multi-frequency phased array probe (2.5–3.5 MHz)1.
The exam was performed according to a standard pro-
cedure with concurrent continuous electrocardiographic
monitoring [16]. High-quality video clips were acquired
and stored using the echo machine software for off-line
measurements. All measurements of interest were re-
peated on 3 consecutive cardiac cycles, and the mean
value was used in the statistical analysis [17].
B-mode and M-mode echocardiography were used to
define valve morphology and structures, including the
type of lesions and the presence/absence of valvular pro-
lapse, while the degree of mitral regurgitation (MR), if
present, was assessed by the use of colour Doppler, cal-
culating the maximal ratio of the regurgitant jet area sig-
nal to LA area (ARJ/LAA ratio) [17]. The left atrial toaortic root ratio (LA/Ao) was measured as previously
described [4, 18]. Diagnosis of MVD was based on 2-D
and colour Doppler echocardiographic findings: charac-
teristic valvular lesions of the mitral valve apparatus and
a demonstrated MR on the colour Doppler echocardio-
gram were considered as the definitive diagnostic cri-
teria, as previously described [17].
The M-mode-derived end-diastolic volume index
(EDVI) and the end-systolic volume index (ESVI) were
calculated for each patient using the Teichholtz method
[19]. The area length method was used for the calcula-
tion of 2-D derived parameters: EF%, EDVI and ESVI for
each patient.
Based on body weight, the values for LVIDad (left ven-
tricle internal diameter allometric diastole) and LVIDas
(left ventricle internal diameter allometric systole) were
also calculated according the formulas proposed by
Cornell et al. (2004) [20].
The 12 enrolled subjects were stratified into three
groups according to the guidelines for the diagnosis and
treatment of chronic valvular heart disease established
by the American College of Veterinary Internal Medicine
Consensus Statement (ACVIM) [21].
Group H included 4 healthy subjects (stage A of
ACVIM) with a normal clinical history, examination,
thoracic radiography, echocardiography, serum biochem-
istry, and complete blood count (CBC) [21].
Group M included 4 asymptomatic affected dogs
(stages B1 and B2 of ACVIM) with a systolic heart
murmur, echocardiographic evidence of MVD and no
radiographic signs of venous congestion or pulmonary
edema [21].
Group S included 4 symptomatic CKCS (stage C and
D of ACVIM) with clinical and radiographic signs of
heart failure and echocardiographic evidence of MVD
[21]. All of the dogs of the S group were treated with
chronic pharmacologic therapy for heart failure includ-
ing furosemide, angiotensin-converting enzyme inhibi-
tors and pimobendan at the recommended dosage
(Atkins et al. 2009). None of them received spironolac-
tone or other potassium-sparing diuretics.
Serological proteome analysis (SERPA)
Before analysis, the frozen serum was thawed slowly
at room temperature [22, 23]. The serum samples
were analysed through 2D electrophoresis. The first-
dimensional analysis was performed using Immobiline
Dry strips (pH 3-7 NL, length 7 cm, GE-Healthcare).
Immobiline Dry strips were rehydrated overnight in a buf-
fer containing 7 M urea, 2 M thiourea, 4% 3-[(3-Cholami-
dopropyl) dimethylammonio]-1-propanesulfonate hydrate
(CHAPS), 1% threo-1,4-Dimercapto-2,3-butanediol, DL-
Dithiothreitol, Cleland’s reagent (DTT), 2% ampholine pH
3.5–10 and 0.002% bromophenol blue. One hundred μg of
Table 1 Population characteristics
ID Age (years) Sex Weight (kg) MVD severity
1 3 F 11,5 H
2 2 F 6,8 H
3 1,5 F 9 H
4 3 F 7 H
5 2 M 7,5 M
6 5,5 F 5 M
7 10 FS 9 M
8 7 F 9 M
9 9 M 8 S
10 7 M 12 S
11 11 FS 9,5 S
12 9 M 8 S
MVD mitral valve disease, F female, M male, FS neutered female, H healthy
dogs, M mild affected, S severe affected
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the cathodic side. Isoelectric focusing was performed
using the Protean IEF (Isoelectric Focusing) Cell Sys-
tem (Bio-Rad). For IEF, the following protocol was
used: 100 V (4h), 250 V (2h), 5000 V (5h), 5000 V
(50000 Volt-hrs).
After the first dimension run was completed, the strips
were equilibrated with a solution containing 6 M urea,
20% glycerol, 2% SDS and 50 mM Tris–HCl (pH 8.8),
with the addition of 1% w/v DTT in the first step and
2.5% w/v iodoacetamide in the second step. For the
second dimension, the proteins were separated by SDS-
PAGE on 10% polyacrylamide gels using the Mini
Protean System (Biorad, USA). Molecular weight protein
markers (Precision Plus - BioRad) were applied on one
end of the IPG strips. In the second dimension, the gels
were run at 7.5 mA/gel for 20 min and then at 15 mA/gel
until the bromophenol blue ran off of the gel. The gels
were stained with Coomassie G250.
All images were acquired using an Image Scanner III
(GE Healthcare, Uppsala). The gel images were imported
into Progenesis SameSpot v4.5 software (Nonlinear
Dynamics, UK) for analysis. All of the imported images
were processed with Progenesis SameSpots to check
image quality (saturation and dimension). The aligned
images were then automatically analysed using the 2D
analysis module for spot detection, background subtrac-
tion, normalization, and spot matching, and all spots
were manually reviewed and validated to ensure proper
detection and matching.
Statistical analysis
The statistical analysis of the echocardiographic vari-
ables, the electrolyte concentrations and the haemato-
logical parameters was performed using SAS statistical
software (SAS version 11 SW; SAS Institute, Cary, North
Carolina, USA). Medians and ranges were calculated,
and p-values less than 0.05 were considered statistically
significant. The differences among the categories were
assessed using the Kruskal-Wallis test, followed by a
paired Wilcoxon test.
Statistical analysis of the proteomic data was performed
using the Progenesis Stats module on the log-normalized
volumes for all spots. The Stats module automatically per-
formed a one-way ANOVA on each spot to evaluate the
p-value between different groups, with p-values under
0.05 considered statistically significant.
MALDI TOF MS protein identification
Single spots were excised from the Coomassie-stained
2DE gels, and the spots, previously reduced and alky-
lated, were digested with a solution of 0.01 μg/μl of por-
cine trypsin at 37 °C for 16 h. The reaction was stopped
with 1% TFA in H2O (v/v). The peptides were desaltedand concentrated by a C18 ZipTip (Millipore) and then
co-crystallized with a solution of 0.5 mg/ml α-ciano-4-
hydroxycinnamic acid (HCCA) on a Ground Steel plate
(Bruker-Daltonics, Bremen, Germany) previously spotted
with a thin layer of a 10 mg/ml HCCA solution. Mass
spectra were acquired with an Ultraflex III MALDI-
TOF/TOF spectrometer (Bruker-Daltonics) in a positive
reflectron mode and processed with FlexAnalysis 3.1
software (Bruker-Daltonics) for the selection of the
monoisotopic peptide masses. External and internal
calibrations were performed. After exclusion of con-
taminant ions (known matrix and human keratin
peaks), the created peak lists were analysed by the
MASCOT v.2.4.1 algorithm (www.matrixscience.com)
against the NCBI_201410 database restricted to Canis
Lupus Familiaris (class: Other Mammalia). The query
for database searching was performed with the carba-
midomethylation of cysteines as a fixed modification,
the oxidation of methionines as a variable modifica-
tion, and one missed cleavage site allowed for trypsin
at 70 ppm as a maximal tolerance. Mascot protein scores
greater than 74 were considered significant (p < 0.05) for
protein identification assignment. To confirm PMF identi-
fications, the instrument was switched to LIFT mode;
MS/MS spectra were acquired and processed by Flex-
Analysis 3.0 software (Bruker-Daltonics).
Results
The 4 dogs in the H group were significantly younger
than those in the M group (2.3 vs 6.1 years, p = 0.0380)
and those in the S group (9 versus 2.3 years, p = 0.0284).
There were no significant differences by sex and weight
between the three groups (Table 1). The normal reference
values, the medians and ranges of the echocardiographic
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groups are reported in Table 2 [20, 24, 25].
The electrolyte normal values and their levels in the
H, M and S groups are reported in Table 3 [26]. Serum
sodium levels showed a statistically significant decrease
in subjects in the S group compared with the M and the
H groups (p = 0.0228 and p = 0.0256, respectively), and
serum calcium levels also decreased significantly in sub-
jects belonging to the S group compared to the H group
(p = 0.0304).
Serum potassium and chloride and the levels of other
biochemical analytes (creatinine and urea) were not sig-
nificantly different among the three groups.
Red blood cells and haematocrit values decreased in
group S versus the M and H groups, but the differences
were not statistically significant (Table 3) [27].
Proteomics analysis (SERPA 2DE and MALDI-TOF-MS)
Proteomics analysis highlighted a total of eight proteins
differentially expressed among the groups (data shown
in Table 4). Figure 1 shows the relative 2D map with dif-
ferentially expressed proteins excised from the gel for
MALDI- TOF MS analysis.
Five proteins were found to be down-regulated and one
protein was up-regulated (p ≤ 0.05) in group M versus H.
The down-regulated proteins included complement factor
H isoform 2 (gi|74005944), inhibitor of carbonic
anhydrase (gi|545538999), haemopexin (gi|73988725),
dystrobrevin beta isoform X7 (gi|545527237) and CD5
molecule-like (gi|545505255). Fibronectin type-III domain-
containing protein 3A isoform X4 (gi|545537390) was
found to be up-regulated in the M group versus the
H group.Table 2 Echocardiographic variables in all dogs and in each groups
Variables M mode Normal value Over all population (12 dogs)
LVIDs (mm) * 15.2 ± 4.8 19.8 (15.9-31.4)
LVIDd (mm) * 26 ± 4.7 30.95 (25.1-49.8)
LVIDas 0.71-1.26 0.94 (0.82-1.63)
LVIDasd 1.27-1.85 1.77 (1.22-2.7)
ESVI (ml/m2) <30 31.9 (17-96)
EDVI (ml/m2) <100 105.8 (43-287)
EF% * 70 ± 9.20 67.5 (38-86)
Variables 2D
LA/Ao * 1.22 ± 0.31 1.3 (0.9-3.1)
ESVI (ml/m2) <30 24 (18-42)
EDVI (ml/m2) <70 53.5 (31-167)
LVIDd was significantly increased in dogs in group S compared with dogs in group
group S compared with group H (p = 0.0304). M-mode-derived EDVI was significant
The ratio of left atrial to aorta root was significantly increased in dogs in group S th
difference was found in the LVIDs, LVIDas, ESVI (M-mode), ESVI and EDVI (2-D) FS%
Data are reported as median and ranges (minimum-maximum). *Data are expressedFive proteins were found to be down-regulated in
group S versus group H: complement factor H isoform 2
(gi|74005944), calpain-3 isoform X2 (gi|545549554),
dystrobrevin beta isoform X7 (gi|545527237), CD5
molecule-like (gi|545505255) and l-2-hydroxyglutarate
dehydrogenase (mitochondrial isoform 2, gi|345804340).
As shown in Table 4, complement factor H isoform 2,
calpain-3 isoform X2, dystrobrevin beta isoform X7,
CD5 molecule-like and hydroxyglutarate dehydrogenase
were found to be down-regulated in group M versus
group H. All of these proteins except complement factor
H followed a decreasing trend according to the progres-
sion of the pathology.
Discussion
To our knowledge, this is the first proteomic study on
serum proteins in CKCS affected by MVD. In this study,
the differential proteomic profiles of CKCS dogs affected
by MVD with different degrees of severity, as well as
healthy controls, has been analysed.
This study was focused mostly on proteins differen-
tially expressed in mildly affected dogs (group M) in
comparison to healthy controls in order to provide com-
plementary tools for the early detection of this pathology
and/or in the evaluation of its stage/severity.
The group M (or the mildly affected dogs) represented
a valuable pool of samples for the study of this pathology
in its subclinical status. Nevertheless, all groups have
been analysed and, the proteomics profiling of advanced
stages provided a more complete overview of the trends
of the expression of each protein. The average expres-
sion of each protein in all groups of CKCS has been rep-
resented in Table 4.of severity
Group H (4 dogs) Group M (4 dogs) Group S (4 dogs)
19.1 (16.2-20.7) 19.2 (17.7-22.6) 19.45 (15.9-31.4)
29.75 (25.1-31.1) 30.1 (25.3-33.9) 39.65 (34.6-49.8)
0.92 (0.87-1.12) 1.11 (0.93-1.15) 0.92 (0.82-1.63)
1.61 (1.22-1.77) 1.65 (1.30-1.91) 1.97 (1.86-2.7)
23.9 (19.9-37.1) 37.9 (39.3-23.8) 36.5 (17.4-96.1)
84.9 (43.4-104.7) 91.3 (59-125.7) 157.5 (120-287.9)
69 (38-78) 61.5 (51-69) 83 (66-86)
1.2 (0.9-1.3) 1.2 (0.9-1.6) 2.14 (1.6-3.1)
24.5 (18-30) 20 (17-26) 41 (40-42)
45 (37-54) 54.5 (31-68) 123.5 (80-167)
H (p = 0.0304) and with dogs in group M (p = 0.0304). LVIDad was increased in
ly increased in dogs in group S compared with dogs in group H (p = 0.0304).
an in group M (p = 0.0304) and group H (p = 0.0304). No statistically significant
and EF% (M-mode and 2-D) among the groups
as means values ± standard deviation
Table 3 Electrolytes levels, red blood cells count (RBCC) and hematocrit reported as median and ranges (minimum–maximum) in all
dogs and in each groups of severity
Normal Value Over all population Group H (4 dogs) Group M (4 dogs) Group S (4 dogs)
Serum Calcium (mg/dl) 8.98-11.82 10.6 (9-12.2) 11.65 (11.3-11.9) 10.6 (9.3-12.2) 9.75 (9-10.1)
Serum Potassium (mmol/l) 3.7 – 5.8 4.6 (4.3-5.2) 4.75 (4.5-4.9) 4.65 (4.3-5.2) 4.45 (4.3-4.6)
RBCC (x106/ μl) 5.5-8.5 6.23 (5.64-7.08) 6.45 (6.16-6.87) 6.1 (5.64-7.08) 6 (5.45-6.28)
Hematocrit (%) 35 - 55 37.4 (32.2-40.1) 36.55 (33.8-40.1) 37.6 (37.4-38.4) 35.9 (32.2-40.1)
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pexin was found to be down-regulated in M group in
comparison to H group. It is an acute-phase protein that
can bind and transport haeme to the liver for breakdown
and iron recovery, after which the free hemopexin
returns to circulation [8]. Hemopexin also acts as a
multifunctional agent in important processes such as
iron homeostasis, antioxidant protection, and signalling
pathways to promote cell survival and gene expression.
This has important implications in several pathologic
conditions not only associated with the release of heme
but also in the control of the immune response and in
the pathogenesis of renal and cardiovascular diseases
[28]. The haemopexin down-regulation found in CKCS
belonging to the M group is in accordance with the re-
sults reported by Ge Gao et al. [8]. In humans affectedTable 4 Protein identification by MALDI-TOF-TOF analysis
H healthy, M medium, S severe, CV variation coefficient, Mr relative Mass, pI isolectr
cPeptide Mass Fingerprinting score calculated by MASCOT 2.4.1 algorithm (http://w
of experimental peptides matched versus searched peptides; fAminoacidic sequenc
parent iones used for MS/MS analysisby degenerative mitral valve disease; however, these au-
thors did not advance any hypothesis on the underlying
mechanisms, and more studies were advocated [8, 29].
Moreover, Krekken et al. reported the relationship
between hemopexin and angiotensin II through the
regulation of the vascular angiotensin II type 1 receptor
(AT1-R) [28]. These evidences could provide new hy-
potheses on the remodelling processes induced by this
pathology especially in the light of their correlation with
the disease. Finally, the decreased levels of the hemo-
pexin we found in asymptomatic dogs could be related
to the binding of the free heme produced by the haem-
olysis described in dogs affected by MVD due to the
blood turbulences in the left atrium [30].
The carbonic anhydrase family (CAs) includes zinc
metalloenzymes that catalyse the reversible hydration-ic point, aName of identified proteins; bAccession No. according to database
ww.matrixscience.com) after database search; d sequence coverage; e Number
e of the peptides identified by MS/MS analysis; gMonoisotopic masses of the
Fig. 1 2D map showing the position of the protein spots analyzed by MALDI TOF MS. The red arrows and the numbers indicated correspond to
the dataset showed in Table 3 indicating the differential expression pattern among experimental groups
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a role in many physiological and biological processes in-
cluding calcification, acid-base balance, ion transport,
and bone absorption; in vitro, it also promotes the for-
mation of CaCO3. Calcium salt precipitation is an
important step in tissue calcification, and valvular calcifi-
cation is one of the common and key pathological
changes in MVD [8]. Using the same experimental
approach, Gao and colleagues [8] identified the over-
representation of Carbonic anhydrase 1 in human
patients of Valvular Heart Diseases. This result seems to
be consistent with the down-regulation of the inhibitor
of carbonic anhydrase we found in mildly affected dogs.
This result could be linked to the expression of calcium
and to an improper mineralization process by the accel-
eration of calcium salt deposition on the mitral valve
leaflets [8]. Moreover, the negative trend in the calcium
levels in the serum from healthy dogs to those severely
affected is in accordance with the down-regulation of
the inhibitor of carbonic anhydrase evidenced in our
study.
The fibronectin type-III domain-containing protein 3A
isoform X4 was found to be over-represented in M vs H
experimental group. This protein contains in its se-
quence domains of fibronectin that has been already
described to be up-regulated [11] and its function is re-
lated to cell adhesion and is involved in the processes of
tissue remodelling [11, 31].In humans, the fibronectin type-III domain-containing
protein 3A is as well involved in cell-cell adhesion among
cells of the same organism according to GO annotations.
Its putative role in this pathology is still unknown and
needs further investigation but it can be considered im-
portant in the process of cardiac tissue remodelling.
In severely affected dogs, a significantly low sodium
concentration was found in comparison with other
groups; according to the literature, this could be due to
the influence of the therapy, as Boswood observed that
chloride tends to significantly decrease with the adminis-
tration of treatment [32, 33]. The serum levels of potas-
sium showed a decrease in the H group compared with
the S group; however, this variation was not statistically
significant.
All of the CKCS included in the study belonging to
the S group received furosemide, which might be the
reason for the lower potassium levels in the more se-
verely affected dogs [32].
Furosemide could also be considered responsible for
the significantly lower levels of serum calcium found in
the dogs belonging to group S, as loop diuretics reduce
the activity of the sodium-potassium-chloride cotran-
sporter (NKCC2), which stimulates paracellular calcium
reabsorption, causing an increase in renal calcium losses
and hypocalcemia [34].
In our population, no significant alterations in haemo-
globin, red blood cells or haematocrit were found.
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also considered as a breed-specific idiopathic condition
rather than a pathological feature in this study, consist-
ent with other previously published studies [35–37].
Among other differentially expressed proteins, dystro-
brevin beta isoform X7 was found to be down-regulated
(Table 4) in the M and S groups in comparison to the H
group, with a positive correlation with the disease sever-
ity. The role of dystrobrevin in hypertrophic cardiomy-
opathy has already been demonstrated in humans [38].
This evidence demonstrates how the impairment of the
α-dystrobrevin gene (which also encodes for the β form)
is linked to the development of cardiovascular diseases.
Its strong down-regulation in MVD affected CKCS dogs,
could suggest a role in the onset of this disease.
Complement factor H isoform 2 and CD5 molecule-like
have also been found to be related to the severity of the
pathology. The role of these proteins in the pathology still
has to be elucidated; proteomic analysis of human plasma
in chronic rheumatic mitral stenosis has revealed proteins
involved in the complement and coagulation cascades [39].
However, their statistically significant down-regulation both
in the M and S groups could suggest a role as molecular
markers for this pathology.
This study reports a novel finding on canine MVD
from the point of view of protein expression; however,
there were several limitations. One of these concern the
possibility that the changes in protein patterns, observed
in each severity group, might be consistent with disease
processes different from MVD. Nowadays the clinical
examination and, above all the conventional Echo-
Doppler exam represent the diagnostic gold standard of
canine MVD. Nevertheless the lacking of post-mortem
examination might represents a limitation to take in ac-
count [17]. Furthermore the relatively small sample size
of each group could have resulted in less significant
changes in the electrolyte concentrations compared with
other studies, and, also the therapy could have influ-
enced the electrolyte balance in the subjects belonging
to the S group.
Another limitation was that the stratification of the pa-
tients takes into account the presence (group S) or ab-
sence (group M) of symptoms, and the ACVIM classes B1
and B2 CKCS are in the same strata. This limit must be
considered in the next study, as the cardiac remodelling
process that could be present in ACVIM class B2 and not
in B1 could cause different protein expression patterns.
This is a pilot study and clearly further prospective co-
hort researches are needed to confirm our results, how-
ever, finding the same proteins on all groups of dog
could be considered a confirmation of their functional
importance, and encourage further investigations in
studying the protein expression patterns in dogs affected
by MVD.Conclusion
The genetic and the proteomics studies of MVD are im-
portant for providing additional information for the
comprehension of this pathology and for the evaluation
of the outcome of this disease. Obtained results and fur-
ther studies on these different parameters may contrib-
ute to the improvement of the genetic selection of pure
breeds to reduce the incidence of this pathology. More-
over, protein identified that were found to be positively
or negatively related to the pathology may be helpful in
the future for the diagnosis, for choosing the best thera-
peutic approach and for evaluating the therapeutic re-
sponse to improve the quality of life and the clinical
outcome in dogs affected by MVD.
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